SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-031371
Filing Date
2023-03-13
Accepted
2023-03-10 20:51:36
Documents
12
Period of Report
2023-03-10
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm239243d1_8k.htm   iXBRL 8-K 25066
  Complete submission text file 0001104659-23-031371.txt   197971

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA knsa-20230310.xsd EX-101.SCH 3030
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE knsa-20230310_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE knsa-20230310_pre.xml EX-101.PRE 22593
6 EXTRACTED XBRL INSTANCE DOCUMENT tm239243d1_8k_htm.xml XML 3612
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 7814399100
Kiniksa Pharmaceuticals, Ltd. (Filer) CIK: 0001730430 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38492 | Film No.: 23725436
SIC: 2834 Pharmaceutical Preparations